Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 11,447 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $6.22, for a total transaction of $71,200.34. Following the sale, the director now directly owns 7,098,428 shares in the company, valued at $44,152,222.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, September 17th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.84, for a total value of $78,297.48.
• On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.27, for a total value of $71,772.69.
• On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.12, for a total value of $81,502.64.
• On Tuesday, August 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.82, for a total value of $78,068.54.
• On Tuesday, July 23rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.48, for a total value of $97,070.56.
• On Tuesday, July 9th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.32, for a total transaction of $83,792.04.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $6.11 on Friday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average price is $6.88 and its two-hundred day moving average price is $8.09. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $15.74. The stock has a market capitalization of $1.45 billion, a P/E ratio of -3.82 and a beta of 0.80.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. During the same quarter in the previous year, the company posted ($0.38) earnings per share. The firm’s revenue for the quarter was up 30.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Jefferies Financial Group decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. KeyCorp reduced their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Needham & Company LLC decreased their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $9.40.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in RXRX. Benjamin F. Edwards & Company Inc. bought a new position in shares of Recursion Pharmaceuticals during the first quarter worth about $26,000. GAMMA Investing LLC boosted its stake in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares during the period. Amalgamated Bank grew its position in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the last quarter. Midwest Financial Group LLC bought a new position in Recursion Pharmaceuticals in the 2nd quarter worth about $90,000. Finally, Xponance Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at approximately $98,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.